

The Role of Medication in Substance Use Treatment

References

Mystery of Change – What factors affect treatment and recovery efforts?

1. Gordon AJ, Zrull M. Social networks and recovery: one year after inpatient treatment. *J Subst Abuse Treat.* 1991;8:143–52.
2. Montgomery HA, Miller WR, Tonigan SJ. Does alcoholics anonymous involvement predict treatment outcome? *J Subst Abuse Treat.* 1995;12:241-6.
3. Moos RH, Finney JW, Cronkite RC. *Alcoholism Treatment: Context, Process, and Outcome.* New York: Oxford University Press. 1990.
4. Moos RH, Moos BS. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. *Addiction.* 2006;101(2):212-22.

Dopamine and Reward I

1. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc Natl Acad Sci U S A.* 1988;85:5274-78.
2. Koob GF, Bloom FE. Cellular molecular mechanism of drug dependence. *Science.* 1988;242:715-23.
3. Brodie MS, Pesold C, Appel SB. Ethanol directly excites dopaminergic ventral tegmental area reward neurons. *Alcohol Clin Exp Res.* 1999;23:1848-52.
4. Volkow ND, Wang G-J, Fowler JS, et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. *J Pharmacol Exp Ther.* 1991;291:409-15.
5. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. *Biol Psychiatry.* 2001;49:81-96.

Dopamine and Reward II

1. Martel P, Fantino M. Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study. *Pharmacol Biochem Behav.* 1996;53:221-6.
2. Fiorino DF, Coury A, Phillips AG. Dynamic changes in nucleus accumbens dopamine efflux during the Coolidge effect in male rats. *J. Neurosci.* 1997;17:4849-55.

Natural Reward vs. Substance-Induced Reward

1. Volkow ND, Wang GJ, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. *Nature.* 1997;386:827-30.
2. Volkow ND, Fowler JS, Wang, GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. *Behav. Pharmacol.* 2002;13:355-66.
3. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc Natl Acad Sci.* 1988;85:5274-8.

The Role of Medication in Substance Use Treatment

References

Down-Regulation of Dopamine

1. Balldin JI, Berggren UC, Lindstedt G. Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism. *Alcoholism, Clinical and Experimental Research*. 1992;16:71-4.
2. Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. *Nature*. 1997;386:830-3.
3. Volkow ND, Wang GJ, Fowler JS, et al. Cocaine abusers show a blunted response to alcohol intoxication in limbic brain regions. *Life Sciences*. 2000;66:PL161-7.

Reduced Dopamine Availability and Decision Making

1. Fiorino DF, Phillips AG. Facilitation of sexual behavior and enhanced dopamine efflux in the nucleus accumbens of male rats after D-amphetamine behavioral sensitization. *J Neurosci*. 1999;19:456-63.
2. Di Chiara G, Tanda G, Cadoni C, et al. Homologies and differences in the action of drugs of abuse and a conventional reinforcer (food) on dopamine transmission: an interpretive framework of the mechanism of drug dependence. *Adv Pharmacol*. 1998;42:983-7.

Addiction as a Brain Disease

1. Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. *Nat Med*. 1996;2:699-703.
2. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. *Am J Psychiatry*. 2001;158:377-38.
3. Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. *Nature*. 1997;386:830-3.
4. Volkow ND, Wang GJ, Fowler JS, et al. Cocaine abusers show a blunted response to alcohol intoxication in limbic brain regions, *Life Sciences*. 2000;66:PL161-7.
5. George SR, Fan T, Ng GY, et al. Low endogenous dopamine function in brain predisposes to high alcohol preference and consumption: reversal by increasing synaptic dopamine. *J. Pharmacol. Exp. Ther*. 1995;273:373-9.
6. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. *Neurobiol Learn Mem*. 2002;78:610-24.

The Role of Medication in Substance Use Treatment

References

Reversible Changes

1. Hormes JT, Filley CM, Rosenberg NL. Neurologic sequelae of chronic solvent vapor abuse. *Neurology*. 1986;36:698-702.
2. Heinz A, Lichtenberg-Kraag B, Baum SS, et al. Evidence for prolonged recovery of dopaminergic transmission after detoxification in alcoholics with poor treatment outcome. *J Neural Transm Gen Sect*. 1995;102:149-57. Return of DA transporters within 4 weeks of abstinence from alcohol.
3. Laine TP, Ahonen A, Torniainen P, et al. Dopamine transporters increase in human brain after alcohol withdrawal. *Mol Psychiatry*. 1999;4:189-91.
4. McCann UD, Wong DF, Yokoi F, et al. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [¹¹C]WIN-35,428. *J Neurosci*. 1998;18:8417-25.
5. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. *Am J Psychiatry*. 2001;158:377-82.
6. Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. *J Neurosci*. 2001;21:9414-8.

Combining Counseling with Medication I

1. Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction? In: *Integrating Behavior Therapies With Medication in the Treatment of Drug Dependence*. NIDA Research Monograph 150. Edited by Onken LS, Blaine JD, Boren JJ. 1995. Rockville, MD, National Institute on Drug Abuse, 37-52.
2. Carroll KM, Sinha R, Nich C, et al. Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. *Exp Clin Psychopharmacol*. 2002;10:54-63.
3. Amato L, Minozzi S, Davoli M, et al.. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. *Cochrane Database of Systematic Reviews*. 2004, Issue 4.
4. Hughes JR, Francis RJ. Behavioral support programs for smoking cessation. *Mod Med*. 1994;62:22-7.
5. Hughes JR. Treatment of nicotine dependence: is more better? *JAMA*. 1995;274:1390-1.
6. O'Malley, SS. Strategies to maximize the efficacy of naltrexone for alcohol dependence. In: *Integrating psychosocial therapies with pharmacotherapies in the treatment of drug dependence*. Onken LS, Blaine J., Editors, 1995. *NIDA Research Monograph Series*. Number 105, NIH Publication No. 95-3899. National Institute on Drug Abuse, Rockville, MD, pp. 92-109.

The Role of Medication in Substance Use Treatment

References

Combining Counseling with Medication II

1. Ball JC, Ross A. *The effectiveness of methadone maintenance treatment*. New York: 1991. Springer-Verlag.
2. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. *Arch Gen Psychiatry*. 1992;49:881-7.
3. Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics. *Am J Psychiatry*. 1999;156:1758-64.
4. Mattick RP, Ali R, White JM, et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. *Addiction*. 2003;98:441-52.